 Eric Wu
Concepts (463)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Care Costs | 31 | 2022 | 418 | 4.210 |
Why?
| | Hyperkalemia | 4 | 2021 | 27 | 2.590 |
Why?
| | Everolimus | 10 | 2016 | 109 | 2.370 |
Why?
| | Health Resources | 9 | 2022 | 125 | 2.300 |
Why?
| | Cost of Illness | 13 | 2022 | 308 | 2.070 |
Why?
| | Receptor, ErbB-2 | 13 | 2018 | 355 | 1.830 |
Why?
| | Breast Neoplasms | 16 | 2018 | 2294 | 1.540 |
Why?
| | Health Services | 11 | 2016 | 116 | 1.520 |
Why?
| | Antineoplastic Agents | 20 | 2018 | 2162 | 1.460 |
Why?
| | Citalopram | 6 | 2012 | 35 | 1.240 |
Why?
| | Depressive Disorder, Major | 7 | 2012 | 373 | 1.190 |
Why?
| | Health Expenditures | 9 | 2020 | 193 | 1.150 |
Why?
| | Receptors, Estrogen | 3 | 2015 | 440 | 1.150 |
Why?
| | Receptors, Antigen, T-Cell | 4 | 2021 | 719 | 1.120 |
Why?
| | Medication Adherence | 4 | 2015 | 503 | 1.090 |
Why?
| | Psoriasis | 5 | 2018 | 109 | 1.040 |
Why?
| | Immunotherapy, Adoptive | 2 | 2020 | 350 | 1.000 |
Why?
| | Practice Patterns, Physicians' | 6 | 2018 | 1315 | 0.990 |
Why?
| | Insurance Claim Review | 18 | 2017 | 84 | 0.980 |
Why?
| | United States | 52 | 2022 | 15065 | 0.980 |
Why?
| | Hepatitis C, Chronic | 3 | 2019 | 168 | 0.920 |
Why?
| | Pyrimidines | 7 | 2014 | 476 | 0.920 |
Why?
| | Middle Aged | 75 | 2020 | 33867 | 0.910 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2021 | 621 | 0.910 |
Why?
| | Drug Substitution | 3 | 2019 | 56 | 0.900 |
Why?
| | Piperazines | 6 | 2014 | 349 | 0.900 |
Why?
| | Biosimilar Pharmaceuticals | 2 | 2022 | 26 | 0.880 |
Why?
| | Aged | 56 | 2022 | 24237 | 0.820 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 4 | 2012 | 428 | 0.820 |
Why?
| | Receptors, Progesterone | 2 | 2015 | 351 | 0.810 |
Why?
| | Retrospective Studies | 45 | 2022 | 15924 | 0.810 |
Why?
| | Models, Economic | 2 | 2020 | 61 | 0.790 |
Why?
| | Comparative Effectiveness Research | 3 | 2012 | 156 | 0.780 |
Why?
| | Benzamides | 6 | 2014 | 213 | 0.780 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2014 | 125 | 0.760 |
Why?
| | Humans | 122 | 2022 | 139073 | 0.760 |
Why?
| | Antifungal Agents | 4 | 2017 | 141 | 0.760 |
Why?
| | Female | 92 | 2021 | 74078 | 0.750 |
Why?
| | Cost-Benefit Analysis | 15 | 2022 | 605 | 0.750 |
Why?
| | Imatinib Mesylate | 7 | 2014 | 80 | 0.730 |
Why?
| | Central Nervous System Stimulants | 3 | 2012 | 176 | 0.720 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 183 | 0.690 |
Why?
| | Hospital Costs | 3 | 2020 | 120 | 0.690 |
Why?
| | Rheumatology | 1 | 2022 | 110 | 0.690 |
Why?
| | Male | 78 | 2021 | 68330 | 0.670 |
Why?
| | Gout | 2 | 2012 | 38 | 0.670 |
Why?
| | Adult | 57 | 2022 | 38394 | 0.670 |
Why?
| | Hypoglycemic Agents | 4 | 2015 | 1307 | 0.660 |
Why?
| | Acidosis | 1 | 2021 | 105 | 0.660 |
Why?
| | Proportional Hazards Models | 14 | 2017 | 1286 | 0.650 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2018 | 1748 | 0.650 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 290 | 0.650 |
Why?
| | Kaplan-Meier Estimate | 12 | 2018 | 903 | 0.640 |
Why?
| | Nocturia | 1 | 2019 | 9 | 0.640 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1439 | 0.630 |
Why?
| | Databases, Factual | 13 | 2021 | 1404 | 0.610 |
Why?
| | Prevalence | 11 | 2021 | 2746 | 0.610 |
Why?
| | Postmenopause | 7 | 2018 | 376 | 0.600 |
Why?
| | Hospitalization | 15 | 2021 | 2224 | 0.590 |
Why?
| | Medicare | 10 | 2022 | 790 | 0.580 |
Why?
| | Comorbidity | 12 | 2014 | 1656 | 0.570 |
Why?
| | Nutrition Surveys | 1 | 2019 | 270 | 0.560 |
Why?
| | Proline | 2 | 2015 | 82 | 0.550 |
Why?
| | Candida | 2 | 2017 | 41 | 0.550 |
Why?
| | Protein Kinase Inhibitors | 5 | 2014 | 914 | 0.540 |
Why?
| | Leukemia, Myeloid, Chronic-Phase | 2 | 2014 | 3 | 0.540 |
Why?
| | Fluconazole | 1 | 2017 | 21 | 0.530 |
Why?
| | Candidemia | 1 | 2017 | 14 | 0.530 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2017 | 40 | 0.520 |
Why?
| | Cardiologists | 1 | 2017 | 45 | 0.520 |
Why?
| | Fees, Pharmaceutical | 3 | 2016 | 11 | 0.510 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 96 | 0.510 |
Why?
| | Oligopeptides | 2 | 2015 | 272 | 0.500 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2015 | 2515 | 0.500 |
Why?
| | Aftercare | 2 | 2021 | 213 | 0.500 |
Why?
| | Thrombolytic Therapy | 1 | 2017 | 150 | 0.490 |
Why?
| | Cystitis, Interstitial | 2 | 2006 | 20 | 0.490 |
Why?
| | Biological Therapy | 1 | 2016 | 27 | 0.490 |
Why?
| | Antirheumatic Agents | 2 | 2016 | 292 | 0.490 |
Why?
| | Antidepressive Agents, Second-Generation | 3 | 2011 | 50 | 0.480 |
Why?
| | Antiviral Agents | 3 | 2019 | 766 | 0.480 |
Why?
| | Tissue Plasminogen Activator | 1 | 2017 | 231 | 0.470 |
Why?
| | Drug Eruptions | 1 | 2015 | 27 | 0.470 |
Why?
| | Propylamines | 2 | 2012 | 11 | 0.450 |
Why?
| | Costs and Cost Analysis | 10 | 2019 | 222 | 0.450 |
Why?
| | Fibrinolytic Agents | 1 | 2017 | 278 | 0.440 |
Why?
| | Methylphenidate | 2 | 2012 | 42 | 0.440 |
Why?
| | Insulin | 3 | 2015 | 2407 | 0.440 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2014 | 39 | 0.440 |
Why?
| | Diphosphonates | 2 | 2012 | 69 | 0.430 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 358 | 0.430 |
Why?
| | Physicians, Primary Care | 1 | 2017 | 225 | 0.430 |
Why?
| | Health Care Rationing | 2 | 2016 | 62 | 0.430 |
Why?
| | Delivery of Health Care | 2 | 2019 | 961 | 0.420 |
Why?
| | Treatment Outcome | 24 | 2021 | 10965 | 0.420 |
Why?
| | Anemia | 1 | 2015 | 175 | 0.410 |
Why?
| | Brain Ischemia | 1 | 2017 | 343 | 0.410 |
Why?
| | Insurance, Health | 5 | 2011 | 295 | 0.410 |
Why?
| | Imidazoles | 2 | 2012 | 240 | 0.410 |
Why?
| | Hypertension | 5 | 2018 | 1253 | 0.400 |
Why?
| | Neoplasm Metastasis | 8 | 2018 | 668 | 0.400 |
Why?
| | Aged, 80 and over | 14 | 2020 | 7699 | 0.390 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2016 | 168 | 0.390 |
Why?
| | Dextroamphetamine | 1 | 2012 | 4 | 0.380 |
Why?
| | Guanfacine | 1 | 2012 | 5 | 0.380 |
Why?
| | Pharmacoepidemiology | 1 | 2012 | 21 | 0.380 |
Why?
| | Liver Neoplasms | 2 | 2015 | 761 | 0.370 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2012 | 61 | 0.360 |
Why?
| | Antibodies, Monoclonal, Humanized | 9 | 2018 | 817 | 0.360 |
Why?
| | Medicaid | 3 | 2012 | 448 | 0.360 |
Why?
| | Schizophrenia | 2 | 2006 | 451 | 0.360 |
Why?
| | Patient Compliance | 3 | 2011 | 599 | 0.360 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 359 | 0.360 |
Why?
| | Drug Costs | 6 | 2015 | 112 | 0.360 |
Why?
| | Pulmonary Embolism | 1 | 2014 | 234 | 0.350 |
Why?
| | Disease-Free Survival | 7 | 2019 | 704 | 0.350 |
Why?
| | Referral and Consultation | 1 | 2017 | 799 | 0.350 |
Why?
| | Fumarates | 1 | 2011 | 10 | 0.350 |
Why?
| | Drugs, Generic | 1 | 2011 | 25 | 0.340 |
Why?
| | Bone Diseases | 1 | 2011 | 64 | 0.330 |
Why?
| | Triazoles | 4 | 2016 | 156 | 0.330 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2011 | 97 | 0.330 |
Why?
| | Amides | 1 | 2011 | 97 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2015 | 1069 | 0.330 |
Why?
| | Stroke | 2 | 2017 | 1138 | 0.320 |
Why?
| | Heart Failure | 3 | 2020 | 2059 | 0.310 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 196 | 0.310 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 1162 | 0.310 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 324 | 0.310 |
Why?
| | Potassium | 2 | 2021 | 147 | 0.310 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1055 | 0.300 |
Why?
| | Sick Leave | 2 | 2007 | 15 | 0.300 |
Why?
| | Crohn Disease | 5 | 2012 | 250 | 0.300 |
Why?
| | Hyperuricemia | 1 | 2009 | 45 | 0.300 |
Why?
| | Myelodysplastic Syndromes | 2 | 2021 | 141 | 0.300 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2022 | 1248 | 0.300 |
Why?
| | Anticoagulants | 1 | 2014 | 669 | 0.300 |
Why?
| | Quality of Life | 9 | 2021 | 2954 | 0.290 |
Why?
| | Oligonucleotides | 2 | 2019 | 149 | 0.280 |
Why?
| | Absenteeism | 2 | 2005 | 52 | 0.280 |
Why?
| | Uric Acid | 1 | 2009 | 165 | 0.280 |
Why?
| | Risk Factors | 12 | 2017 | 10426 | 0.280 |
Why?
| | Multiple Myeloma | 1 | 2011 | 272 | 0.280 |
Why?
| | Patient Acceptance of Health Care | 7 | 2021 | 855 | 0.270 |
Why?
| | Insurance Claim Reporting | 2 | 2007 | 26 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2012 | 1516 | 0.270 |
Why?
| | Hypoglycemia | 1 | 2012 | 446 | 0.260 |
Why?
| | Physicians | 1 | 2015 | 929 | 0.260 |
Why?
| | Head and Neck Neoplasms | 1 | 2012 | 554 | 0.260 |
Why?
| | Health Status Indicators | 1 | 2007 | 165 | 0.250 |
Why?
| | Pentosan Sulfuric Polyester | 1 | 2006 | 1 | 0.250 |
Why?
| | Economics, Pharmaceutical | 1 | 2006 | 10 | 0.250 |
Why?
| | Drug Therapy, Combination | 6 | 2019 | 1049 | 0.250 |
Why?
| | Drug Resistance, Fungal | 2 | 2017 | 9 | 0.240 |
Why?
| | Treatment Failure | 3 | 2017 | 351 | 0.240 |
Why?
| | Young Adult | 13 | 2020 | 13344 | 0.240 |
Why?
| | Endometriosis | 2 | 2017 | 52 | 0.230 |
Why?
| | Diagnostic Errors | 1 | 2006 | 174 | 0.220 |
Why?
| | Urinary Incontinence | 1 | 2005 | 66 | 0.220 |
Why?
| | Nitriles | 3 | 2016 | 178 | 0.220 |
Why?
| | Adolescent | 21 | 2017 | 21561 | 0.220 |
Why?
| | Immunoglobulin G | 1 | 2008 | 904 | 0.220 |
Why?
| | Prostatic Neoplasms | 2 | 2012 | 1048 | 0.210 |
Why?
| | Emergency Service, Hospital | 4 | 2021 | 2106 | 0.210 |
Why?
| | Recurrence | 3 | 2020 | 1103 | 0.210 |
Why?
| | Electronic Health Records | 2 | 2021 | 1088 | 0.210 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2014 | 431 | 0.200 |
Why?
| | Psychotic Disorders | 1 | 2005 | 172 | 0.200 |
Why?
| | Antihypertensive Agents | 3 | 2012 | 501 | 0.200 |
Why?
| | Molecular Targeted Therapy | 3 | 2015 | 414 | 0.190 |
Why?
| | Genetic Therapy | 2 | 2021 | 314 | 0.180 |
Why?
| | Thiophenes | 2 | 2014 | 122 | 0.180 |
Why?
| | Infliximab | 1 | 2022 | 112 | 0.180 |
Why?
| | Delayed-Action Preparations | 3 | 2017 | 178 | 0.180 |
Why?
| | Population Surveillance | 1 | 2005 | 480 | 0.180 |
Why?
| | Anti-Inflammatory Agents | 3 | 2011 | 475 | 0.180 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2021 | 5 | 0.180 |
Why?
| | Bone Density Conservation Agents | 2 | 2012 | 82 | 0.180 |
Why?
| | Atrial Fibrillation | 1 | 2005 | 377 | 0.170 |
Why?
| | Gastritis | 1 | 2022 | 110 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 1111 | 0.170 |
Why?
| | Gout Suppressants | 2 | 2012 | 21 | 0.170 |
Why?
| | Biological Products | 2 | 2016 | 229 | 0.170 |
Why?
| | Enteritis | 1 | 2022 | 104 | 0.170 |
Why?
| | Severity of Illness Index | 6 | 2018 | 2865 | 0.170 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1049 | 0.170 |
Why?
| | Hemophilia B | 1 | 2021 | 63 | 0.170 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2021 | 94 | 0.170 |
Why?
| | Adenocarcinoma | 1 | 2007 | 884 | 0.170 |
Why?
| | Atomoxetine Hydrochloride | 2 | 2012 | 8 | 0.160 |
Why?
| | Time Factors | 5 | 2017 | 6885 | 0.160 |
Why?
| | Bronchodilator Agents | 2 | 2011 | 197 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2022 | 243 | 0.160 |
Why?
| | Voriconazole | 2 | 2016 | 20 | 0.160 |
Why?
| | National Health Programs | 1 | 2019 | 21 | 0.160 |
Why?
| | Eosinophilia | 1 | 2022 | 219 | 0.160 |
Why?
| | Technology Assessment, Biomedical | 1 | 2019 | 40 | 0.160 |
Why?
| | Aromatase Inhibitors | 2 | 2018 | 60 | 0.160 |
Why?
| | Regression Analysis | 4 | 2012 | 1015 | 0.160 |
Why?
| | Muscular Atrophy, Spinal | 1 | 2019 | 23 | 0.160 |
Why?
| | Patient Readmission | 2 | 2017 | 706 | 0.150 |
Why?
| | Hemophilia A | 1 | 2021 | 141 | 0.150 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2019 | 13 | 0.150 |
Why?
| | Survival Analysis | 4 | 2018 | 1313 | 0.150 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2019 | 18 | 0.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2011 | 1030 | 0.150 |
Why?
| | Health Services Research | 1 | 2021 | 405 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 2 | 2017 | 348 | 0.150 |
Why?
| | Multivariate Analysis | 5 | 2015 | 1498 | 0.150 |
Why?
| | Aging | 1 | 2009 | 1860 | 0.150 |
Why?
| | China | 2 | 2021 | 213 | 0.140 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2015 | 658 | 0.140 |
Why?
| | Time-to-Treatment | 2 | 2017 | 212 | 0.140 |
Why?
| | Urologic Neoplasms | 1 | 2018 | 30 | 0.140 |
Why?
| | Europe | 3 | 2019 | 407 | 0.140 |
Why?
| | Polystyrenes | 1 | 2018 | 37 | 0.140 |
Why?
| | Antidepressive Agents | 2 | 2011 | 245 | 0.140 |
Why?
| | Vital Capacity | 2 | 2015 | 304 | 0.140 |
Why?
| | Managed Care Programs | 2 | 2010 | 140 | 0.140 |
Why?
| | Chronic Disease | 4 | 2014 | 1802 | 0.140 |
Why?
| | 4-Aminopyridine | 1 | 2017 | 25 | 0.140 |
Why?
| | Overweight | 1 | 2022 | 573 | 0.130 |
Why?
| | Retreatment | 1 | 2017 | 73 | 0.130 |
Why?
| | Thiazoles | 2 | 2014 | 127 | 0.130 |
Why?
| | Patient Preference | 1 | 2019 | 197 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2016 | 377 | 0.130 |
Why?
| | Aspergillosis | 1 | 2016 | 22 | 0.130 |
Why?
| | Drug Administration Schedule | 4 | 2013 | 769 | 0.130 |
Why?
| | Administration, Intravenous | 1 | 2017 | 158 | 0.130 |
Why?
| | Abiraterone Acetate | 1 | 2016 | 15 | 0.130 |
Why?
| | Consumer Behavior | 1 | 2017 | 73 | 0.130 |
Why?
| | Mental Disorders | 1 | 2005 | 1091 | 0.130 |
Why?
| | Hysterectomy | 1 | 2017 | 141 | 0.120 |
Why?
| | Administrative Claims, Healthcare | 1 | 2016 | 26 | 0.120 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 50 | 0.120 |
Why?
| | Capecitabine | 1 | 2016 | 42 | 0.120 |
Why?
| | Trastuzumab | 1 | 2016 | 97 | 0.120 |
Why?
| | Prednisone | 1 | 2016 | 227 | 0.120 |
Why?
| | Disability Evaluation | 1 | 2017 | 298 | 0.120 |
Why?
| | Clinical Protocols | 1 | 2017 | 274 | 0.120 |
Why?
| | Patient Admission | 1 | 2017 | 202 | 0.120 |
Why?
| | Androstadienes | 1 | 2015 | 78 | 0.120 |
Why?
| | Patient Discharge | 1 | 2021 | 909 | 0.120 |
Why?
| | Ki-1 Antigen | 1 | 2015 | 6 | 0.120 |
Why?
| | Ambulatory Care | 3 | 2015 | 575 | 0.110 |
Why?
| | International Classification of Diseases | 1 | 2016 | 138 | 0.110 |
Why?
| | Logistic Models | 2 | 2014 | 2089 | 0.110 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2015 | 21 | 0.110 |
Why?
| | Waiting Lists | 1 | 2017 | 259 | 0.110 |
Why?
| | Drug Interactions | 1 | 2016 | 411 | 0.110 |
Why?
| | Neoplasm Staging | 2 | 2015 | 1380 | 0.110 |
Why?
| | Ribavirin | 1 | 2015 | 95 | 0.110 |
Why?
| | California | 2 | 2006 | 442 | 0.110 |
Why?
| | Carboplatin | 1 | 2014 | 146 | 0.110 |
Why?
| | International Normalized Ratio | 1 | 2014 | 49 | 0.110 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2014 | 36 | 0.110 |
Why?
| | Amphotericin B | 1 | 2014 | 33 | 0.110 |
Why?
| | Japan | 3 | 2021 | 128 | 0.110 |
Why?
| | Cytogenetic Analysis | 1 | 2013 | 34 | 0.110 |
Why?
| | Cross-Sectional Studies | 3 | 2019 | 5537 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 633 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1361 | 0.110 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2014 | 95 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2015 | 5167 | 0.100 |
Why?
| | Drug Prescriptions | 1 | 2015 | 259 | 0.100 |
Why?
| | Constipation | 1 | 2014 | 98 | 0.100 |
Why?
| | Immunoconjugates | 1 | 2015 | 123 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2017 | 582 | 0.100 |
Why?
| | Paclitaxel | 1 | 2014 | 237 | 0.100 |
Why?
| | Morpholines | 1 | 2014 | 124 | 0.100 |
Why?
| | ErbB Receptors | 2 | 2016 | 613 | 0.100 |
Why?
| | Mycoses | 1 | 2014 | 82 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 666 | 0.100 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2015 | 231 | 0.100 |
Why?
| | Drug Combinations | 2 | 2011 | 347 | 0.100 |
Why?
| | Pyridines | 1 | 2016 | 498 | 0.100 |
Why?
| | Budgets | 1 | 2012 | 14 | 0.100 |
Why?
| | Hodgkin Disease | 1 | 2015 | 156 | 0.100 |
Why?
| | Warfarin | 1 | 2014 | 155 | 0.100 |
Why?
| | Cohort Studies | 5 | 2016 | 5736 | 0.100 |
Why?
| | Allopurinol | 1 | 2012 | 62 | 0.100 |
Why?
| | Laparoscopy | 1 | 2017 | 453 | 0.100 |
Why?
| | Adalimumab | 5 | 2011 | 53 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2014 | 211 | 0.100 |
Why?
| | New Zealand | 1 | 2012 | 54 | 0.090 |
Why?
| | Lisdexamfetamine Dimesylate | 1 | 2012 | 9 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1036 | 0.090 |
Why?
| | Gastrointestinal Diseases | 1 | 2014 | 209 | 0.090 |
Why?
| | Ethanolamines | 1 | 2012 | 15 | 0.090 |
Why?
| | Health Status | 2 | 2008 | 821 | 0.090 |
Why?
| | Databases as Topic | 2 | 2009 | 69 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2014 | 208 | 0.090 |
Why?
| | Genetic Testing | 1 | 2015 | 457 | 0.090 |
Why?
| | Benzopyrans | 1 | 2012 | 27 | 0.090 |
Why?
| | Pleural Effusion | 1 | 2012 | 56 | 0.090 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2014 | 204 | 0.090 |
Why?
| | Rivaroxaban | 1 | 2014 | 256 | 0.090 |
Why?
| | Estradiol | 1 | 2015 | 525 | 0.090 |
Why?
| | Multiple Sclerosis | 1 | 2017 | 460 | 0.090 |
Why?
| | Florida | 1 | 2012 | 112 | 0.090 |
Why?
| | Sulfonylurea Compounds | 1 | 2012 | 50 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 5892 | 0.090 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2534 | 0.090 |
Why?
| | Neurotransmitter Uptake Inhibitors | 1 | 2011 | 3 | 0.090 |
Why?
| | Fractures, Spontaneous | 1 | 2011 | 16 | 0.090 |
Why?
| | North America | 1 | 2012 | 311 | 0.090 |
Why?
| | Cyclohexanols | 1 | 2011 | 13 | 0.090 |
Why?
| | Child | 6 | 2020 | 21907 | 0.090 |
Why?
| | Hypercalcemia | 1 | 2011 | 20 | 0.090 |
Why?
| | Spinal Cord Compression | 1 | 2011 | 21 | 0.090 |
Why?
| | Australia | 1 | 2012 | 304 | 0.090 |
Why?
| | Cost Sharing | 1 | 2011 | 17 | 0.090 |
Why?
| | Nebulizers and Vaporizers | 1 | 2011 | 68 | 0.090 |
Why?
| | Adamantane | 1 | 2011 | 18 | 0.090 |
Why?
| | Efficiency | 2 | 2011 | 101 | 0.090 |
Why?
| | Models, Statistical | 2 | 2012 | 667 | 0.090 |
Why?
| | Sirolimus | 1 | 2012 | 280 | 0.090 |
Why?
| | Communication | 1 | 2017 | 932 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2014 | 3585 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 1 | 2011 | 64 | 0.080 |
Why?
| | Pyrrolidines | 1 | 2011 | 81 | 0.080 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2011 | 47 | 0.080 |
Why?
| | Norepinephrine | 1 | 2011 | 192 | 0.080 |
Why?
| | Health Benefit Plans, Employee | 2 | 2009 | 27 | 0.080 |
Why?
| | Bone Neoplasms | 1 | 2012 | 249 | 0.080 |
Why?
| | Pyrazines | 1 | 2011 | 88 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2011 | 230 | 0.080 |
Why?
| | Administration, Oral | 1 | 2012 | 790 | 0.080 |
Why?
| | Linear Models | 1 | 2012 | 856 | 0.080 |
Why?
| | Gastrointestinal Agents | 1 | 2009 | 66 | 0.080 |
Why?
| | Drug Utilization | 1 | 2010 | 169 | 0.070 |
Why?
| | Obesity | 1 | 2022 | 3002 | 0.070 |
Why?
| | Etanercept | 1 | 2008 | 59 | 0.070 |
Why?
| | Serotonin | 1 | 2011 | 322 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 2009 | 110 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2008 | 166 | 0.070 |
Why?
| | Age Distribution | 3 | 2015 | 398 | 0.070 |
Why?
| | Depressive Disorder | 1 | 2011 | 390 | 0.070 |
Why?
| | Amphetamines | 1 | 2007 | 6 | 0.070 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2007 | 18 | 0.070 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2007 | 24 | 0.070 |
Why?
| | Employment | 2 | 2007 | 183 | 0.070 |
Why?
| | Digestive System Surgical Procedures | 1 | 2008 | 105 | 0.070 |
Why?
| | Medical Audit | 1 | 2007 | 77 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 2 | 2022 | 109 | 0.070 |
Why?
| | Algorithms | 1 | 2014 | 1722 | 0.060 |
Why?
| | Disease Progression | 4 | 2015 | 2741 | 0.060 |
Why?
| | Age Factors | 3 | 2015 | 3276 | 0.060 |
Why?
| | Veterans Disability Claims | 1 | 2006 | 3 | 0.060 |
Why?
| | Laboratories | 1 | 2007 | 108 | 0.060 |
Why?
| | Private Sector | 1 | 2006 | 54 | 0.060 |
Why?
| | Employer Health Costs | 1 | 2005 | 3 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 374 | 0.060 |
Why?
| | Ischemic Attack, Transient | 1 | 2006 | 67 | 0.060 |
Why?
| | Metabolic Diseases | 1 | 2007 | 109 | 0.060 |
Why?
| | Atrial Flutter | 1 | 2005 | 31 | 0.060 |
Why?
| | Hallucinations | 1 | 2005 | 32 | 0.060 |
Why?
| | Double-Blind Method | 4 | 2011 | 1947 | 0.060 |
Why?
| | Area Under Curve | 1 | 2005 | 315 | 0.060 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 237 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 1889 | 0.050 |
Why?
| | Administration, Inhalation | 3 | 2011 | 595 | 0.050 |
Why?
| | Dasatinib | 2 | 2014 | 56 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2007 | 348 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 496 | 0.050 |
Why?
| | Anti-Asthmatic Agents | 1 | 2006 | 266 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2011 | 804 | 0.050 |
Why?
| | Data Collection | 1 | 2006 | 663 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2005 | 560 | 0.050 |
Why?
| | Body Weight | 1 | 2007 | 995 | 0.050 |
Why?
| | Lung | 1 | 2015 | 4094 | 0.050 |
Why?
| | Bevacizumab | 2 | 2014 | 139 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 803 | 0.050 |
Why?
| | Health Policy | 1 | 2005 | 396 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2005 | 806 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1497 | 0.040 |
Why?
| | Veterans | 1 | 2013 | 1479 | 0.040 |
Why?
| | Glucagon-Like Peptides | 1 | 2022 | 59 | 0.040 |
Why?
| | Information Storage and Retrieval | 1 | 2021 | 118 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2011 | 2051 | 0.040 |
Why?
| | Mental Health Services | 1 | 2005 | 433 | 0.040 |
Why?
| | Infant | 4 | 2019 | 9576 | 0.040 |
Why?
| | Asia | 1 | 2019 | 70 | 0.040 |
Why?
| | Azacitidine | 1 | 2021 | 141 | 0.040 |
Why?
| | Remission Induction | 2 | 2011 | 295 | 0.040 |
Why?
| | France | 1 | 2019 | 36 | 0.040 |
Why?
| | Spain | 1 | 2019 | 45 | 0.040 |
Why?
| | Incidence | 1 | 2006 | 2836 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2007 | 3317 | 0.040 |
Why?
| | Italy | 1 | 2019 | 111 | 0.040 |
Why?
| | Germany | 1 | 2019 | 127 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2018 | 47 | 0.030 |
Why?
| | Sex Factors | 2 | 2015 | 2056 | 0.030 |
Why?
| | Neutropenia | 1 | 2018 | 158 | 0.030 |
Why?
| | Potassium Channel Blockers | 1 | 2017 | 42 | 0.030 |
Why?
| | Disease Management | 2 | 2015 | 620 | 0.030 |
Why?
| | Models, Econometric | 1 | 2016 | 36 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 413 | 0.030 |
Why?
| | Veterans Health | 1 | 2018 | 186 | 0.030 |
Why?
| | Itraconazole | 1 | 2016 | 8 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2020 | 856 | 0.030 |
Why?
| | Antineoplastic Protocols | 1 | 2014 | 2 | 0.030 |
Why?
| | Utilization Review | 1 | 2014 | 40 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2007 | 2057 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2015 | 237 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 482 | 0.030 |
Why?
| | Aspergillus | 1 | 2014 | 18 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2015 | 152 | 0.030 |
Why?
| | Genes, abl | 1 | 2013 | 4 | 0.030 |
Why?
| | Hypothyroidism | 1 | 2014 | 73 | 0.030 |
Why?
| | Cryptococcus | 1 | 2014 | 15 | 0.030 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2014 | 59 | 0.030 |
Why?
| | Peripheral Vascular Diseases | 1 | 2014 | 103 | 0.030 |
Why?
| | Medication Therapy Management | 1 | 2014 | 77 | 0.030 |
Why?
| | Mood Disorders | 1 | 2014 | 135 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1310 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2013 | 58 | 0.020 |
Why?
| | Myocardium | 1 | 2018 | 922 | 0.020 |
Why?
| | Propensity Score | 1 | 2014 | 312 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1011 | 0.020 |
Why?
| | Atenolol | 1 | 2012 | 8 | 0.020 |
Why?
| | Nebivolol | 1 | 2012 | 10 | 0.020 |
Why?
| | Metoprolol | 1 | 2012 | 25 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1093 | 0.020 |
Why?
| | Propanolamines | 1 | 2012 | 39 | 0.020 |
Why?
| | Carbazoles | 1 | 2012 | 56 | 0.020 |
Why?
| | Risk | 1 | 2014 | 913 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 946 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 38 | 0.020 |
Why?
| | Nervous System Diseases | 1 | 2014 | 273 | 0.020 |
Why?
| | Duloxetine Hydrochloride | 1 | 2011 | 13 | 0.020 |
Why?
| | Venlafaxine Hydrochloride | 1 | 2011 | 14 | 0.020 |
Why?
| | Cetuximab | 1 | 2011 | 98 | 0.020 |
Why?
| | Sitagliptin Phosphate | 1 | 2011 | 33 | 0.020 |
Why?
| | Tablets | 1 | 2010 | 41 | 0.020 |
Why?
| | State Medicine | 1 | 2009 | 25 | 0.020 |
Why?
| | Critical Care | 1 | 2015 | 648 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 1235 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2009 | 95 | 0.020 |
Why?
| | Blood Glucose | 2 | 2011 | 2191 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 162 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2010 | 233 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2009 | 204 | 0.020 |
Why?
| | United Kingdom | 1 | 2009 | 321 | 0.020 |
Why?
| | Probability | 1 | 2009 | 309 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1084 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 431 | 0.020 |
Why?
| | Canada | 1 | 2009 | 412 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 336 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 805 | 0.020 |
Why?
| | Sex Distribution | 1 | 2008 | 380 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2846 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 4024 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1818 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1320 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2013 | 2822 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2706 | 0.010 |
Why?
| | Health Status Disparities | 1 | 2008 | 299 | 0.010 |
Why?
| | Child, Preschool | 2 | 2007 | 11142 | 0.010 |
Why?
| | Emergency Medical Services | 1 | 2007 | 565 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 3470 | 0.010 |
Why?
| | Body Mass Index | 1 | 2007 | 2388 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6152 | 0.010 |
Why?
|
|
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|